The AR is an important mediator in the development and progression of prostate cancers, including the progress of the aggressive and often lethal form of androgen-independent disease. Androgen ablation therapy is the most common treatment for advanced prostate cancer, senior study author, Yun Qiu offers from the University of Maryland School of Medicine. But many patients inevitably develop deadly recurrent cancer that androgen blockade androgen blockade and are resistant to current therapies. .

the findings imply RNF6 an important regulator of AR transcriptional activity. Our work suggests that the ubiquitination of AR, and possibly other transcription factors, to modulate function as a scaffold for cofactor recruitment transcriptional activity and specificity, concludes Dr. targeting components of the ubiquitination machinery, such RNF6 can potentially effective in the treatment of advanced prostate cancer. .. The important changes, inhibition or interference with ubiquitination of AR expression RNF6 a specific group of AR target genes and abrogated recruitment of AR and its required coactivators to androgen-responsive regulatory regions in these genes.Thus , researchers can test the ability of groove pathway inhibitors by descendants of to compel cancer stem of differentiating into harmless goblet cell. The so goblet cell are no longer able encourage cancer growth,’said Chandler. ‘There may a particular hack inhibitor of or similar drug anything is required recurrences and metastasis, which the following often being prevent a first reaction to treatment. This new tool will help us to to determine whether the so – be.